3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Interventions
Cyclophosphamide
13
Temozolomide
10
Magnetic Resonance Spectroscopy
10
dinutuximab
8
X-Rays
8
Specimen Handling
8
Irinotecan
8
Biopsy
8
Phantoms, Imaging
7
Topotecan
6
Nuclear Medicine Department, Hospital
6
fludarabine
5
Vincristine
5
3-Iodobenzylguanidine
5
fludarabine phosphate
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Etoposide
4
tipifarnib
3
sargramostim
3
Radiotherapy
3
Melphalan
3
Isotretinoin
3
Filgrastim
3
Doxorubicin
3
Carboplatin
3
ulixertinib
2
tazemetostat
2
selpercatinib
2
saponin QA-21V1
2
pembrolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroblastoma
×
CLR1404
×
90 days
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled